311 related articles for article (PubMed ID: 25881209)
1. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
3. Differential accumulation of tau pathology between reciprocal F1 hybrids of rTg4510 mice.
Yanagisawa D; Hamezah HS; Pahrudin Arrozi A; Tooyama I
Sci Rep; 2021 May; 11(1):9623. PubMed ID: 33953293
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C
J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229
[TBL] [Abstract][Full Text] [Related]
6. In vivo axonal transport deficits in a mouse model of fronto-temporal dementia.
Majid T; Ali YO; Venkitaramani DV; Jang MK; Lu HC; Pautler RG
Neuroimage Clin; 2014; 4():711-7. PubMed ID: 24936422
[TBL] [Abstract][Full Text] [Related]
7. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
Chen F; David D; Ferrari A; Götz J
Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
[TBL] [Abstract][Full Text] [Related]
8. Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5.
Yanagisawa D; Hamezah HS; Durani LW; Taguchi H; Tooyama I
PLoS One; 2018; 13(12):e0208440. PubMed ID: 30521594
[TBL] [Abstract][Full Text] [Related]
9. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent impairment of memory and neurofibrillary tangle formation and clearance in a mouse model of tauopathy.
Kubota T; Kirino Y
Brain Res; 2021 Aug; 1765():147496. PubMed ID: 33894222
[TBL] [Abstract][Full Text] [Related]
11. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
12. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
[TBL] [Abstract][Full Text] [Related]
13. CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy.
Joly-Amado A; Hunter J; Quadri Z; Zamudio F; Rocha-Rangel PV; Chan D; Kesarwani A; Nash K; Lee DC; Morgan D; Gordon MN; Selenica MB
Front Immunol; 2020; 11():997. PubMed ID: 32508844
[TBL] [Abstract][Full Text] [Related]
14. Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
Bailey RM; Howard J; Knight J; Sahara N; Dickson DW; Lewis J
Mol Neurodegener; 2014 Jan; 9():8. PubMed ID: 24428919
[TBL] [Abstract][Full Text] [Related]
15. Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice.
Rostgaard N; Jul PH; Garmer M; Volbracht C
J Integr Neurosci; 2023 Sep; 22(5):135. PubMed ID: 37735138
[TBL] [Abstract][Full Text] [Related]
16. Cornel Iridoid Glycoside Suppresses Hyperactivity Phenotype in rTg4510 Mice through Reducing Tau Pathology and Improving Synaptic Dysfunction.
Ma DL; Luo Y; Huang R; Zhao ZR; Zhang L; Li YL; Wang Q; Li L; Zhang L
Curr Med Sci; 2020 Dec; 40(6):1031-1039. PubMed ID: 33428130
[TBL] [Abstract][Full Text] [Related]
17. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
18. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
[TBL] [Abstract][Full Text] [Related]
19. Analysis of in vivo turnover of tau in a mouse model of tauopathy.
Yamada K; Patel TK; Hochgräfe K; Mahan TE; Jiang H; Stewart FR; Mandelkow EM; Holtzman DM
Mol Neurodegener; 2015 Oct; 10():55. PubMed ID: 26502977
[TBL] [Abstract][Full Text] [Related]
20. Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.
Blackmore T; Meftah S; Murray TK; Craig PJ; Blockeel A; Phillips K; Eastwood B; O'Neill MJ; Marston H; Ahmed Z; Gilmour G; Gastambide F
Alzheimers Res Ther; 2017 Sep; 9(1):77. PubMed ID: 28931441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
